SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
EXAS Analysis & Videos »
EXAS: Bull or Bear?
EXACT Sciences (NASDAQ: EXAS): Buy and Hold for Long-Term Upside
EXAS
|
|
|
-1.52%
in
28 days
EXACT Sciences (NASDAQ: EXAS) is a molecular diagnostics company that is developing a next-generation (V3), stool DNA (sDNA) based screening test for colorectal cancer (CRC) which has demonstrated the ability to detect both early-stage cancer and pre-cancerous growths. The Company's sDNA-based screening technology platform has also demonstrated the ability to detect related GI cancers and pre-cancers. <> Only 24% of an estimated 90 million individuals in the U.S. are currently compliant with CRC screening recommendations, which results in an estimated 68 million people who are non-compl...
|
EXACT Sciences (NASDAQ: EXAS): Patience Required for Long-Term Upside
EXAS
|
|
|
+6.48%
in
4 days
(closed on 11/07/09)
On 11/3/09, EXACT Sciences (NASDAQ: EXAS) reported its 3Q09 results and held a conference call to outline the Company’s progress and timeline for the development of a stool DNA based test kit for the early diagnosis and prevention of colorectal cancer (CRC). EXAS reported total revenue of $1.3 million (which primarily reflects non-cash recognition of Genzyme deal earlier this year), a net loss of $1 million, operating expenses of $2.3 million, and ended the quarter with cash / equivalents of $26.9 million. <> Last week, EXAS made a SEC 8-K filing regarding its President / CEO,...
|
BioMed News Bytes: Rockwell Medical, EXACT Sciences, MannKind
EXAS
|
|
|
-0.81%
in
5 days
(closed on 11/03/09)
BioMed News Bytes: Rockwell Medical, EXACT Sciences, MannKind The BioMedReports.com FDA Calendar service includes a database with over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results. <> On 10/29/09, MannKind (NASDAQ: MNKD) announced that results of two Phase 1 studies demonstrate that the novel, investigational ...
|
Rodman Conference Recaps: EXACT Sciences, Delcath, Unilife
EXAS
|
|
|
-6.46%
in
20 days
(closed on 10/03/09)
<> <> On 8/31/09, Delcath Systems (NASDAQ:DCTH) announced the FDA granted orphan drug status to doxorubicin, an approved chemotherapy agent, for the treatment of primary liver cancer. The Company said it tested doxorubicin with its unique drug delivery technology, Percutaneous Hepatic Perfusion (PHP), which results in significantly higher doses (e.g. 10X the FDA approved standard dosing with 100X exposure of drug to the tumor site) of anti-cancer drugs such as doxorubicin to the liver without exposing the patient's entire body. Delcath plans to carry out the necessary clinical work for a regul...
|
EXACT Sciences: Smaller Phase 3 Study Will Save Time, Money
EXAS
|
|
|
+13.51%
in
30 days
(closed on 09/13/09)
The <font> stock research section of BioMedReports.com </font> has been updated on 8/14/09 to reflect new developments following the 2Q09 conference call and business update for EXACT Sciences (NASDAQ:EXAS) as the Company prepares for a Phase 3 study next year to obtain FDA marketing clearance for its next-generation stool DNA (sDNA) screening test (V3) for colorectal cancer (CRC) and pre-cancers. The following is a summary of the highlights, projections, and expected milestones from my updated report for EXAS. <> <font> <>http://biomedreports.com/articles/most-popular/585...
|
New Indexes to Track Healthcare Trends and More
EXAS
|
|
|
-8.16%
in
10 days
(closed on 08/14/09)
Below are links and descriptions for 23 new stock indexes I have created, revised, and tracked over the past few years which are now featured at a new website called Investars YOU. The new site includes automated index tracking, allows investors to create custom stock portfolios based on their individual preferences, and now features free access to all of the component stocks in each of my indexes. Some of the top performing stocks from my healthcare indexes on a year-to-date basis are highlighted below.
Cosmetic & Restorative Medicine Index: Allergan (NYSE:AGN) (+38%) <> The <> ...
|
EXACT Sciences (NASDAQ:EXAS): Back on Track, Report Available
EXAS
|
|
|
+1.46%
in
17 days
(closed on 08/01/09)
EXACT Sciences (NASDAQ:EXAS) provides a timely case study on the current debate over healthcare reform in the U.S. Our current “sick-care” system focuses on the treatment of disease rather than preventative medicine initiatives through investments in wellness programs and improved diagnostic screening tests – particularly in the area of cancer screening since this represents a fast-growing, costly disease. <> <> The Company’s n<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< /><><>< /><><>< />< />< />< /><>< />< /><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
New Index of Cancer Diagnostic and Therapeutic Stocks
EXAS
|
|
|
+158.49%
in
94 days
(closed on 07/15/09)
By Mike Havrilla on 4/12/09 at BioMedReports.com The table at the link below includes statistics for the 40 companies in the ETF Innovators Emerging Cancer Diagnostic and Therapeutic Stock Index, which is featured at BioMedReports.com in the health indexes section of the site. The index will track the performance of stocks with market caps below $200M at the inception date of 4/12/09 from a starting value of 2,632. <> A World Health Organization report released last year es...
|
BioMed Stock Movers: DNDN, EXAS, KG
EXAS
|
|
|
-7.56%
in
20 hours
(closed on 04/09/09)
Dendreon (DNDN) has stalled out around $6.50 per share after a major rally on news of upcoming presentation at a medical conference later this month. DNDN expects to report Provenge clinical trial results some time before the end of April, although it did not guarantee this would occur at the upcoming presentation. The recent spike in shares of DNDN and upcoming presentation do not provide any clarity on whether Provenge results will be sufficient for attaining FDA approval and the pending data release will determine the Company's fate. <> <> <>http://biomedreports.com/article...
|
EXACT Sciences Forms Pact with Genzyme
EXAS
|
|
|
-40.83%
in
49 days
(closed on 03/18/09)
EXACT Sciences Forms Pact with Genzyme After the market close, EXACT Sciences announced that it formed a strategic pact with Genzyme (GENZ), which represents the grounds for the Board's refusal two weeks ago in response to Sequenom's (SQNM) hostile exchange offer at $1.50 per share in stock. The announcement followed news in the pre-market today that SQNM planned to commence its exchange offer through 3/24/09, valuing EXAS at $41M. <> However, the GENZ deal included the pur...
|
Healthcare Hot Spots Beyond Stem Cells
EXAS
|
|
|
+14.18%
in
2 days
(closed on 01/28/09)
Beyond Stem Cells: Healthcare Hot Spots With the surprise announcement last week by Geron (GERN) that the FDA would allow human clinical trials for embryonic stem cells, all companies in the underlying ETF Innovators Index to track the space are screaming higher again today – led by the company with the biggest gains over the past year, StemCells (STEM). <> Below are three additional areas and associated companies for investors to consider in the search of the next hot s...
|
New Preventive Medicine Index
EXAS
|
|
|
-0.66%
in
1 day
(closed on 01/26/09)
One of the major reasons behind Pfizer's (PFE) interest in acquiring Wyeth (WYE) is the latter's focus on products outside of traditional pharmaceuticals – with 60% of Wyeth's revenue from last year derived from biological therapeutics and vaccines. It remains to be seen what happens to Wyeth's proposed deal to acquire Dutch vaccine maker Crucell (CRXL); however since it is much smaller (around $1B) and focuses on the development of vaccines, Pfizer would likely be interested in both companies together. <> With the focus on preven...
|
People Bullish on EXAS
People Bearish on EXAS
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on EXAS |
Be the first to start a discussion and earn 2 points.
More Resources
|
About EXACT Sciences Corp.
- Answers.com
